New cell therapy network to help protect North Rhine-Westphalia against pandemics
On Ash Wednesday, Minister Prof. Dr. Andreas Pinkwart visited the project partner Miltenyi Biotec to find out about the progress of the whole project.
"We urgently need promising therapeutic approaches for long-term pandemic management," said Prof. Dr. Andreas Pinkwart, Minister for Economic Affairs, Innovation, Digitalization and Energy of North Rhine-Westphalia. "There are currently several hundred research projects worldwide. The state of North Rhine-Westphalia is one of the forerunners in this respect and, with its universities, clinics and companies, possesses outstanding know-how in the field of infectious diseases. I am very pleased that we can make an important contribution to COVID research with the expertise of the project partners here in North Rhine-Westphalia."
Establishing a NRW-wide infrastructure
But in the long term, the network could also benefit the treatment of other diseases. For example, cell therapy is already being used very successfully for leukemia and could also be effective against other types of cancer in the future. Research is already being conducted worldwide into further potential applications.
Clinical research tests cell therapy approach
"The study will include patients with moderate COVID-19 disease or at risk for severe disease progression. We want to use this novel therapy to prevent the need for intensive care treatment and worsening of the patient’s health. A first step in this process is to test whether the therapy can be used safely," explains Univ. Prof. Dr. Michael Hallek, Director of Clinic I for Internal Medicine at Cologne University Hospital.
A total of between six and twelve patients are to be treated as part of this first study. "The positive outcomes of a recently published study in Spain give us hope. We are confident that this treatment approach will also be able to show a therapeutic effect in the Phase I study at the University Hospital of Cologne. This would help affected patients to survive the disease better and faster," sums up Dr. Boris Stoffel, CEO of Miltenyi Biotec.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services dedicated to supporting biomedical research and advancing cellular therapy. Our innovative solutions support research at all levels, from basic and translational research to clinical applications. Our technologies enable cell research, cell therapy and cell manufacturing solutions used by scientists and clinicians around the world. Our more than 30 years of experience span research areas such as immunology, stem cell biology, neuroscience and cancer. Today, Miltenyi Biotec employs approximately 4,000 people in 23 countries - all helping researchers and clinicians to make a greater contribution to science and healthcare.
Media Contact
Miltenyi Biotec B.V. & Co. KG
Holger Bülow
Corporate Communications
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach
Germany
Phone +49 2204 8306-6680
press@miltenyi.com